Recent breakthroughs in the field of obesity treatment have presented a novel drug known as ALLUVI Retatrutide. This compound is a {highlyspecific GLP-1 receptor agonist, engineered to stimulate the effects of natural glucagon-like peptide-1. Retatrutide has shown impressive outcomes in clinical trials, highlighting significant reductions in body w